- Zhifei Biological reported a preliminary net income decline of 67% to 77% for the fiscal year.
- The estimated preliminary net income for the year is between 1.86 billion yuan and 2.66 billion yuan.
- This figure is significantly lower than the previously estimated net income of 6.03 billion yuan.
- Analyst recommendations for Zhifei Biological include 16 buys and 3 holds, with no sell recommendations.
“`
A look at Chongqing Zhifei Biological Products Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 5 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Analysts utilizing the Smartkarma Smart Scores have provided insights into the long-term outlook for Chongqing Zhifei Biological Products Company Ltd. With a strong Value score of 4 and a top-notch Dividend score of 5, the company is seen as having solid fundamentals and a healthy dividend payout. However, its Growth and Resilience scores at 3 each suggest room for improvement in these areas. In terms of Momentum, the company scored a 2, indicating a slower rate of price appreciation in the near future. Overall, Chongqing Zhifei Biological Products is positioned well for value and dividends, although areas for growth and resilience could be areas to focus on.
Chongqing Zhifei Biological Products Company Ltd. specializes in researching, manufacturing, and selling vaccines and biological products, including prevention products, blood products, diagnostic reagents, and therapeutic agents. The company’s impressive Dividend score of 5 reflects its commitment to rewarding shareholders, while its Value score of 4 indicates strong underlying financials. Although the Growth and Resilience scores stand at 3, showing areas for potential enhancement, the company’s Momentum score of 2 suggests a slower pace of future price movement. Investors may find Chongqing Zhifei Biological Products an attractive option for dividends and value, with opportunities available for growth and improved resilience in the long run.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
